We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

Viking Therapeutics stock plunged Thursday on a relatively light earnings report that included mostly incremental updates for its highly anticipated weight-loss drugs. Please watch the video at ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the firm, Ratings reports. One equities ...

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed ...

Citi analyst David Lebowitz maintained a Hold rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $38.00.